**Question:** Clopidogrel is an antiplatelet agent that acts by:

**Core Concept:** Clopidogrel is a prodrug, which means it needs to be converted into its active form to exert its effects. Once converted, clopidogrel competitively inhibits the binding of adenosine diphosphate (ADP) to its receptor on platelet surface. This results in decreased platelet aggregation and reduced formation of blood clots.

**Why the Correct Answer is Right:** Clopidogrel belongs to the class of drugs known as thienopyridines. When it reaches the liver, it is converted into its active form, which is a sulfhydryl (SH) group-containing compound. This active form specifically binds to and inhibits the P2Y12 adenosine diphosphate (ADP) receptor on platelets, leading to a decrease in the binding of ADP to its receptor. As a result, platelet aggregation is inhibited, and the formation of blood clots is reduced.

**Why Each Wrong Option is Incorrect:**

A. This option is incorrect because clopidogrel inhibits platelet aggregation by interacting with the ADP receptor, not by inhibiting cyclooxygenase (COX) enzymes like aspirin.

B. This option is incorrect because clopidogrel primarily acts on the ADP receptor, not by interfering with thromboxane synthesis like aspirin.

C. This option is incorrect as clopidogrel works by inhibiting the ADP receptor, not by interfering with cAMP or cGMP pathways like prostacyclin.

D. This option is incorrect because clopidogrel inhibits platelet aggregation via the ADP receptor, not by selectively blocking the TXA2 receptor like ticlopidine.

**Clinical Pearl:** Clopidogrel is often used in conjunction with aspirin to achieve synergistic antiplatelet effects for preventing ischemic events in patients with cardiovascular diseases, such as coronary artery disease, stroke, or peripheral artery disease. This combination therapy is essential to reduce the risk of major cardiovascular events like myocardial infarction (heart attack) and stroke.